tbuckley/cabot-search huggingface dataset:
Genomic Signatures of Coevolution between Nonmodel Mammals and Parasitic Roundworms
Authors: Yibo Hu, Lijun Yu, Huizhong Fan, Guangping Huang, Qi Wu, Yonggang Nie, Shuai Liu, Li Yan, Fuwen Wei
Journal: Molecular Biology and Evolution (2020)

Antagonistic coevolution between host and parasite drives species evolution. However, most of the studies only focus on parasitism adaptation and do not explore the coevolution mechanisms from the perspective of both host and parasite. Here, through the de novo sequencing and assembly of the genomes of giant panda roundworm, red panda roundworm, and lion roundworm parasitic on tiger, we investigated the genomic mechanisms of coevolution between nonmodel mammals and their parasitic roundworms and those of roundworm parasitism in general. The genome-wide phylogeny revealed that these parasitic roundworms have not phylogenetically coevolved with their hosts. The CTSZ and prolyl 4-hydroxylase subunit beta (P4HB) immunoregulatory proteins played a central role in protein interaction between mammals and parasitic roundworms. The gene tree comparison identified that seven pairs of interactive proteins had consistent phylogenetic topology, suggesting their coevolution during host-parasite interaction. These coevolutionary proteins were particularly relevant to immune response. In addition, we found that the roundworms of both pandas exhibited higher proportions of metallopeptidase genes, and some positively selected genes were highly related to their larvae's fast development. Our findings provide novel insights into the genetic mechanisms of coevolution between nonmodel mammals and parasites and offer the valuable genomic resources for scientific ascariasis prevention in both pandas.
Mitochondrial DNA copy number can influence mortality and cardiovascular disease via methylation of nuclear DNA CpGs
Authors: Christina A. Castellani, Ryan J. Longchamps, Jason A. Sumpter, Charles E. Newcomb, John A. Lane, Megan L. Grove, Jan Bressler, Jennifer A. Brody, James S. Floyd, Traci M. Bartz, Kent D. Taylor, Penglong Wang, Adrienne Tin, Josef Coresh, James S. Pankow, Myriam Fornage, Eliseo Guallar, Brian O’Rourke, Nathan Pankratz, Chunyu Liu, Daniel Levy, Nona Sotoodehnia, Eric Boerwinkle, Dan E. Arking
Journal: Genome Medicine (2020)

Mitochondrial DNA copy number (mtDNA-CN) has been associated with a variety of aging-related diseases, including all-cause mortality. However, the mechanism by which mtDNA-CN influences disease is not currently understood. One such mechanism may be through regulation of nuclear gene expression via the modification of nuclear DNA (nDNA) methylation.
406MO Sequencing paired tumor DNA and white blood cells (WBCs) increases sensitivity to track plasma circulating tumor DNA (ctDNA) for detecting minimal residual disease (MRD) in localized colon cancer (CC)
Authors: N. Tarazona, J. Martín-Arana, R. Tébar-Martínez, P. Lombardi, S. Moragón, S. Zuñiga, P. Rentero-Garrido, J.A. Carbonell-Asins, V. Gambardella, M. Huerta, S. Roselló, C. Martínez-Ciarpaglini, C. Alfaro-Cervello, D. Moro, A. Ferrer-Martínez, M. Ponce, A. Peña, A. Espí, D. Roda, A. Cervantes
Journal: Annals of Oncology (2020)
Response to: ‘Correspondence to ‘Prevalence of hospital PCR-confirmed COVID-19 cases in patients with chronic inflammatory and autoimmune rheumatic diseases“ by Wu et al
Authors: Jose L Pablos, María Galindo, Ricardo Blanco, José M Alvaro-Gracia
Journal: Annals of the Rheumatic Diseases (2020)

We thank Wu et al for their interest in our study reporting on the prevalence of COVID-19 in patients with rheumatic diseases (RMD).1 Wu et al suggest that potential detection bias due to more frequent regular visits to hospitals in patients with RMD may explain the observed greater prevalence of hospital COVID-19 cases in these patients. However, this is highly unlikely since the identification of hospital PCR+ cases was performed in April 2020, still in the peak phase of COVID-19 pandemic in Spain, when the regular scheduled follow-up visits had been cancelled and restricted to urgent medical care. In addition, PCR test shortage resulted in the need to restrict testing to ‘COVID-19-likely’ symptomatic patients at emergency departments, making unlikely preferential testing of RMD or other specific patients. Nevertheless, we cannot exclude other biases such as greater …
226P Impact of BMI on outcome and cardiac safety in HER2-positive breast cancer patients treated with adjuvant trastuzumab: Results of a monocentric observational study
Authors: C. Molinelli, L. Del Mastro, S. Giraudi, A. Ballestrero, F. Carli, F. Poggio, A. D'Alonzo, C. Dellepiane, G. Buzzatti, E. Blondeaux, B. Conte, S. Pastorino, M. Gallo, M. Lambertini, C. Bighin
Journal: Annals of Oncology (2020)
1823P Characterization of thrombosis risk in patients with cancer: Preliminary results
Authors: P. Cerezuela, I. García Escobar, M. Salgado, R. Molina, A. Araújo, E. Horváth, R. Porta-Balanya, J.C. Benitez Montanez, M. Lobo de Mena, C. Font, E. Martí, F. Garicano, B. Campos Balea, E. Martínez de Castro, M. Malheiro, A.L. Costa, E. Colomé, V.E. Castellón Rubio, E. Gallardo, J. Trujillo Santos
Journal: Annals of Oncology (2020)
Delphi developed syllabus for the medical specialty of sport and exercise medicine: part 2
Authors: David Humphries, Rod Jaques, H Paul Dijkstra, Irfan Asif, Mark E Batt, Mats Borjesson, Emin Ergen, Celeste Geertsema, Boris Gojanovic, Anca Ionescu, Dina Christina Janse van Rensburg, Constance Lebrun, Nahar Azmi Mohamed, Margo Mountjoy, Tvisha Parikh, Diana Robinson, Robert Sallis, Martin Schwellnus, Padraig Sheeran
Journal: British Journal of Sports Medicine (2020)

Training in the medical specialty of sport and exercise medicine (SEM) is available in many, but not all countries. In 2015, an independent Delphi group, the International Syllabus in Sport and Exercise Medicine Group (ISSEMG), was formed to create a basic syllabus for this medical specialty. The group provided the first part of this syllabus, by identifying 11 domains and a total of 80 general learning areas for the specialty, in December 2017. The next step in this process, and the aim of this paper was to determine the specific learning areas for each of the 80 general learning areas. A group of 26 physicians with a range of primary medical specialty qualifications including, Sport and Exercise Medicine, Family Medicine, Internal Medicine, Cardiology, Rheumatology and Anaesthetics were invited to participate in a multiple round online Delphi study to develop specific learning areas for each of the previously published general learning areas. All invitees have extensive clinical experience in the broader sports medicine field, and in one or more components of sports medicine governance at national and/or international level. SEM, Family Medicine, Internal Medicine, Cardiology, Rheumatology and Anaesthetics were invited to participate in a multiple round online Delphi study to develop specific learning areas for each of the previously published general learning areas. All invitees have extensive clinical experience in the broader sports medicine field, and in one or more components of sports medicine governance at national and/or international level. The hierarchical syllabus developed by the ISSEMG provides a useful resource in the planning, development and delivery of specialist training programmes in the medical specialty of SEM.
907P Invasive aspergillosis caused by aspergillus non-fumigatus in children and adults after hematopoietic stem cell transplantation (HSCT) & chemotherapy
Authors: Y. Rogacheva, M. Popova, A. Siniaev, A. Volkova, I. Markova, I. Nikolaev, O. Pinegina, S. Ignatieva, T. Bogomolova, A. Gevorgayn, O. Paina, T. Bykova, Y. Vlasova, O. Goloshchapov, M. Vladovskaya, S. Bondarenko, N. Klimko, L. Zubarovskaya
Journal: Annals of Oncology (2020)
Abstract #3284: Nicotine enhances the antiapoptotic function of Mcl-1 through phosphorylation
Authors: Xingming Deng, Meiguo Xin, Ton Wang, Tammy Flagg, Fengqin Gao
Journal: Cancer Research (2009)

Lung cancer has a strong etiological association with cigarette smoking. Nicotine, a major component in tobacco smoke, functions as a survival agonist that inhibits apoptosis following various stresses. However, the mechanism of action remains elusive. Mcl-1, a major antiapoptotic protein of the Bcl2 family, is extensively expressed in both small cell (SCLC) and non-small cell lung cancer (NSCLC) cells, suggesting that Mcl-1 may be a therapeutic target of patients with lung cancer. Here we found that nicotine-induces Mcl-1 phosphorylation through activation of ERK1/2 in association with increased chemoresistance of human lung cancer cells. Since nicotine stimulates Mcl-1 phosphorylation and survival in cells expressing WT but has no such effects in cells expressing T163A Mcl-1 mutant, this indicates that nicotine induces Mcl-1 phosphorylation exclusively at the T 163 site and that phosphorylation of Mcl-1 at T163 is required for nicotine-induced survival. Mechanistically, nicotine-induced Mcl-1 phosphorylation significantly enhances the half-life of Mcl-1 (i.e. from 2-3 h to 6-8h), which renders Mcl-1 a long-term survival activity. Specific depletion of Mcl-1 by RNA interferenceblocks nicotine-stimulated survival and enhances apoptotic cell death. Thus, nicotine-enhanced survival of lung cancer cells may occur through activation of Mcl-1 by phosphorylation at T163 site, which may contribute to development of human lung cancer and/or chemoresistance.  Citation Information: In: Proc Am Assoc Cancer Res; 2009 Apr 18-22; Denver, CO. Philadelphia (PA): AACR; 2009. Abstract nr 3284.
1375P Predicting chemotherapy toxicity in elderly patients with advanced non-small cell lung cancer: A prospective multicenter study of the national hospital organization in Japan
Authors: M. Shimokawa, M. Kanazu, R. Saito, M. Mori, A. Tamura, Y. Okano, Y. Fujita, T. Endo, M. Motegi, S. Takata, T. Kita, N. Sukoh, M. Takenoyama, S. Atagi
Journal: Annals of Oncology (2020)
911O Performance of dual p16 and HPV testing for determining prognosis in cancer of the oropharynx, the EPIC-OPC Study
Authors: H. Mehanna, M. Taberna Sanz, S. Tous, J. Brooks, C. von Buchwald, M. Mena, N. Batis, R.H. Brakenhoff, R. Baatenburg de Jong, J.P. Klussmann, T. Dalianis, H. Mirghani, A. Schache, J.A. James, S.H. Huang, M.A. Broglie, M. Hoffmann, L. Alemany
Journal: Annals of Oncology (2020)
1141P EXCITE: An analysis of the metastatic melanoma patient experience in the advent of novel therapies using health-related social media
Authors: G. Faust, A. Booth, E. Merinopoulou, S. Halhol, H. Tosar, A. Nawaz, M. Szlachetka, G. Chiu
Journal: Annals of Oncology (2020)
1391P Phase III confirmatory efficacy and safety study of proposed bevacizumab biosimilar (MYL-1402O) compared with avastin, in the first-line treatment of patients with stage IV non-squamous non-small cell lung cancer (nsNSCLC)
Authors: M.A. Socinski, C. Waller, T. Idris, I. Bondarenko, A. Luft, K. Beckmann, A. Vishweswaramurthy, S. Loganathan, G. Ranganna, A. Barve
Journal: Annals of Oncology (2020)
LBA61 First analysis of RAIN-701: Study of tarloxotinib in patients with non-small cell lung cancer (NSCLC) EGFR Exon 20 insertion, HER2-activating mutations &amp; other solid tumours with NRG1/ERBB gene fusions
Authors: S.V. Liu, L.C. Villaruz, V.H.F. Lee, V.W. Zhu, C.S. Baik, A. Sacher, C.E. McCoach, D. Nguyen, J.Y-C. Li, J.M. Pacheco, C. Kim, T.F. Burns, E.L. Schenk, N. Leighl, L. Tozzi, D.R. Camidge
Journal: Annals of Oncology (2020)

Tarloxotinib is a hypoxia-activated prodrug of a pan-ErbB kinase inhibitor that releases a potent irreversible active metabolite (tarloxotinib-E) under hypoxic conditions to preferentially deliver the active moiety to tumor versus normal tissues. Tarloxotinib has shown preclinical efficacy in EGFR exon 20 and HER2 mutant non-small cell lung cancer (NSCLC) as well as other oncogenic alterations in the ERBB gene family such as NRG1 fusions. We report the first results of the RAIN-701 trial (NCT03805841). Patients (pts) with advanced NSCLC harboring an EGFR Exon 20 insertion (Cohort A) or HER2 activating mutation (Cohort B) with progressive disease after platinum-based chemotherapy or with any solid tumors harboring an NRG1, EGFR, HER2 or HER4 fusion (cohort C) were eligible. Enrollment was based on local genomic testing. Tarloxotinib was administered at 150 mg/m2 IV weekly. The primary endpoint is objective response rate per RECIST v1.1. As of June 12, 2020, 23 pts (11 cohort A, 11 cohort B, 1 cohort C) were treated with tarloxotinib. The disease control rate for all evaluable pts was 60% (12/20). In cohort A, the best response was stable disease (SD) in 6/11 (55%) and progressive disease (PD) in 5/11 (45%). In cohort B, 4/9 evaluable pts (44%) exhibited tumor reduction by RECIST and 2/9 pts experienced confirmed PR (22%), 4/9 (44%) pts had SD, and 3/9 (33%) pts had PD. Three pts in cohort B were treated beyond 6 months with 3 pts still ongoing. Most treatment emergent adverse events (TEAEs) were grade 1/2. Those occurring at >20% were prolonged QTc (60.9%), rash (43.5%), nausea (21.7%), and diarrhea (21.7%). The grade 3 TEAEs were prolonged QTc (34.8%), rash (4.3%), diarrhea (4.3%) and increased ALT (4.3%). Five of 23 (21.7%) pts required dose reduction and only 1/23 (4.3%) pts discontinued tarloxotinib due to a drug-related adverse event (infusion reaction). Tarloxotinib exhibits antitumor activity in NSCLC pts with HER2 activating mutations. Tarloxotinib was well tolerated and exhibited low rates of severe EGFR-related toxicities such as rash and diarrhea.
785P Thromboembolic events (TE) during treatment with cisplatin-based chemotherapy (CBCT) in metastatic testicular germ-cell cancer (TC)
Authors: H.S. Sagstuen Haugnes, H.F.S. Negaard, H. Jensvoll, T. Wilsgaard, T. Tandstad, A. Solberg
Journal: Annals of Oncology (2020)
236P Changes in eating habits and food preferences in breast cancer patients undergoing adjuvant chemotherapy: The “CHANGE” prospective study
Authors: C. Gurizzan, P. Di Mauro, S. Bosio, A. Turla, A. Zanini, S. Monteverdi, M. Ardine, V. Amoroso, L. Vassalli, A. Dalla Volta, E. Simoncini, R. Pedersini, A. Berruti
Journal: Annals of Oncology (2020)
Redefining Left Ventricular Assist Device Indications and Strategies—Reply
Authors: Mandeep R. Mehra, Daniel J. Goldstein
Journal: JAMA Cardiology (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Cardiology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Cardiology journal
Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial
Authors: Leisha A Emens, Francisco J Esteva, Mark Beresford, Cristina Saura, Michelino De Laurentiis, Sung-Bae Kim, Seock-Ah Im, Yifan Wang, Roberto Salgado, Aruna Mani, Jigna Shah, Chiara Lambertini, Haiying Liu, Sanne L de Haas, Monika Patre, Sherene Loi
Journal: The Lancet Oncology (2020)
MAIT cell activation and dynamics associated with COVID-19 disease severity
Authors: Tiphaine Parrot, Jean-Baptiste Gorin, Andrea Ponzetta, Kimia T. Maleki, Tobias Kammann, Johanna Emgård, André Perez-Potti, Takuya Sekine, Olga Rivera-Ballesteros, Sara Gredmark-Russ, Olav Rooyackers, Elin Folkesson, Lars I. Eriksson, Anna Norrby-Teglund, Hans-Gustaf Ljunggren, Niklas K. Björkström, Soo Aleman, Marcus Buggert, Jonas Klingström, Kristoffer Strålin, Johan K. Sandberg, John Tyler Sandberg, Helena Bergsten, Niklas K Björkström, Susanna Brighenti, Marcus Buggert, Marta Butrym, Benedict J. Chambers, Puran Chen, Martin Cornillet, Angelica Cuapio, Isabel Diaz Lozano, Majda Dzidic, Johanna Emgård, Malin Flodström-Tullberg, Jean-Baptiste Gorin, Sara Gredmark-Russ, Alvaro Haroun-Izquierdo, Laura Hertwig, Sadaf Kalsum, Jonas Klingström, Efthymia Kokkinou, Egle Kvedaraite, Hans-Gustaf Ljunggren, Magdalini Lourda, Kimia T Maleki, Karl-Johan Malmberg, Jakob Michaëlsson, Jenny Mjösberg, Kirsten Moll, Jagadeeswara Rao Muvva, Anna Norrby-Teglund, Laura M. Palma Medina, Tiphaine Parrot, Lena Radler, Emma Ringqvist, Johan K. Sandberg, Takuya Sekine, Tea Soini, Mattias Svensson, Janne Tynell, Andreas Von Kries, David Wullimann, André Perez-Potti, Olga Rivera-Ballesteros, Christopher Maucourant, Renata Varnaite, Mira Akber, Lena Berglin, Demi Brownlie, Marco Giulio Loreti, Ebba Sohlberg, Tobias Kammann, Elisabeth Henriksson, Nicole Marquardt, Kristoffer Strålin, Soo Aleman, Anders Sönnerborg, Lena Dillner, Anna Färnert, Hedvig Glans, Pontus Nauclér, Olav Rooyackers, Johan Mårtensson, Lars I. Eriksson, Björn P. Persson, Jonathan Grip, Christian Unge
Journal: Science Immunology (2020)

MAIT cell activation and decline in blood are associated with COVID-19 severity, features that dynamically recover in convalescence.
1815MO Two simplified dexamethasone (DEX)-sparing regimens with NEPA for the prevention of emesis caused by cisplatin (DDP): A phase III, controlled, non-inferiority trial
Authors: L. Celio, D. Cortinovis, A. Cogoni, L. Cavanna, O. Martelli, S. Carnio, E. Collovà, F. Bertolini, F. Petrelli, A. Cassano, R. Chiari, F. Zanelli, I. Vittimberga, A. Letizia, A. Misino, F. Silvestris, E. Bonizzoni, S. Pilotto, S. De Placido, E. Bria
Journal: Annals of Oncology (2020)
1708P Online survey on SARS-CoV-2 infections in cancer patients during a nationwide lockdown in France
Authors: N. Hajjaji, S. Lakhdar, E. Kaczmarek, C. Bellier, S. Bécourt, A. Broyelle, E.I. Girard, S. Giscard, E. Lartigau
Journal: Annals of Oncology (2020)
999P Real-life clinical data of cabozantinib for unresectable hepatocellular carcinoma
Authors: F. Tovoli, V. Dadduzio, S. De Lorenzo, I. Garajovà, F. Marra, F. Trevisani, S. Pini, A. Granito, V. Zagonel, G. Brandi, F. Piscaglia
Journal: Annals of Oncology (2020)
Endotheliopathy Is Induced by Plasma From Critically Ill Patients and Associated With Organ Failure in Severe COVID-19
Authors: Antoine Rauch, Annabelle Dupont, Julien Goutay, Morgan Caplan, Senna Staessens, Mouhamed Moussa, Emmanuelle Jeanpierre, Delphine Corseaux, Guillaume Lefevre, Fanny Lassalle, Karine Faure, Marc Lambert, Alain Duhamel, Julien Labreuche, Delphine Garrigue, Simon F. De Meyer, Bart Staels, Eric Van Belle, Flavien Vincent, Eric Kipnis, Peter J. Lenting, Julien Poissy, Sophie Susen, Dominique Deplanque, Enagnon Kazali Alidjinou, Régis Bordet, Marie-Charlotte Chopin, Ilka Engelmann, Anne Goffard, Myriam Labalette, David Launay, Daniel Mathieu, Claude-Alain Maurage, Boualem Sendid
Journal: Circulation (2020)
LBA27 Phase II multicenter, randomized study to evaluate efficacy and safety of avelumab with gemcitabine/carboplatin (CG) vs CG alone in patients with unresectable or metastatic urothelial carcinoma (mUC) who are ineligible to receive cisplatin-based therapy
Authors: B. Perez Valderrama, D. Castellano Gauna, A. Pinto Marin, B. Mellado Gonzalez, J. Puente, M.A. Climent Duran, M. Domènech, F.J. Vazquez Mazon, J.L. Perez Gracia, T. Bonfill, R. Morales Barrera, I. Ballester Navarro, X. Garcia del Muro, P. Maroto, O.J. Juan Vidal, A. Rodriguez-Vida, J. Bellmunt
Journal: Annals of Oncology (2020)
861P Limited implementation of the ESMO-ESGO (European Society of Gynaecological Oncology)-ESTRO (European Society for Radiotherapy and Oncology) consensus conference recommendations (CCR) on endometrial cancer (EC)
Authors: C. Sessa, N. Colombo, C.L. Creutzberg, N. Concin, P. Wimberger, K.A. Marinoni, J-Y. Douillard, V. Torri, S. Rauh
Journal: Annals of Oncology (2020)
286P Artificial intelligence analysis of advanced breast cancer patients from a phase I trial of trastuzumab deruxtecan (T-DxD): HER2 and histopathology features as predictors of clinical benefit
Authors: S. Modi, B. Glass, A. Prakash, A. Taylor-Weiner, H. Elliott, I. Wapinski, M. Sugihara, K. Saito, J. Kaplan Kerner, R. Phillips, T. Shibutani, K. Honda, A. Khosla, A.H. Beck, J. Cogswell
Journal: Annals of Oncology (2020)
1544P Use of pharmacokinetic parameters of preoperative 5-FU as a prognostic factor in resected pancreatic cancer
Authors: A. Vilalta, A. Urrizola, A. Aldaz, P. Sala Elarre, F. Rotellar, F. Pardo, J.C. Subtil, D. Salas Benito, I. Eguren, A. Chopitea Ortega, J. Rodriguez Rodriguez, M. Ponz-Sarvise
Journal: Annals of Oncology (2020)
Applications and future directions for optical coherence tomography in dermatology*
Authors: B. Wan, C. Ganier, X. Du‐Harpur, N. Harun, F.M. Watt, R. Patalay, M.D. Lynch
Journal: British Journal of Dermatology (2020)

Optical coherence tomography (OCT) is a noninvasive optical imaging method that can generate high‐resolution en face and cross‐sectional images of the skin in vivo to a maximum depth of 2 mm. While OCT holds considerable potential for noninvasive diagnosis and disease monitoring, it is poorly understood by many dermatologists. Here we aim to equip the practising dermatologist with an understanding of the principles of skin OCT and the potential clinical indications. We begin with an introduction to the technology and discuss the different modalities of OCT including angiographic (dynamic) OCT, which can image cutaneous blood vessels at high resolution. Next we review clinical applications. OCT has been most extensively investigated in the diagnosis of keratinocyte carcinomas, particularly basal cell carcinoma. To date, OCT has not proven sufficiently accurate for the robust diagnosis of malignant melanoma; however, the evaluation of abnormal vasculature with angiographic OCT is an area of active investigation. OCT, and in particular angiographic OCT, also shows promise in monitoring the response to therapy of inflammatory dermatoses, such as psoriasis and connective tissues disease. We additionally discuss a potential role for artificial intelligence in improving the accuracy of interpretation of OCT imaging data.
LBA18 Overall survival (os) results from SOLAR-1, a phase III study of alpelisib (ALP) + fulvestrant (FUL) for hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC)
Authors: F. André, E.M. Ciruelos, D. Juric, S. Loibl, M. Campone, I. Mayer, G. Rubovszky, T. Yamashita, B. Kaufman, Y-S. Lu, K. Inoue, Z. Papai, M. Takahashi, F. Ghaznawi, D. Mills, M. Kaper, M. Miller, P.F. Conte, H. Iwata, H.S. Rugo
Journal: Annals of Oncology (2020)
A shedding soluble form of interleukin-17 receptor D exacerbates collagen-induced arthritis through facilitating TNF-α-dependent receptor clustering
Authors: Sihan Liu, Yanxia Fu, Kunrong Mei, Yinan Jiang, Xiaojun Sun, Yinyin Wang, Fangli Ren, Congshan Jiang, Liesu Meng, Shemin Lu, Zhihai Qin, Chen Dong, Xinquan Wang, Zhijie Chang, Shigao Yang
Journal: Cellular and Molecular Immunology (2020)
1258O Amivantamab (JNJ-61186372), an EGFR-MET bispecific antibody, in combination with lazertinib, a 3rd-generation tyrosine kinase inhibitor (TKI), in advanced EGFR NSCLC
Authors: B.C. Cho, K.H. Lee, E.K. Cho, D-W. Kim, J-S. Lee, J-Y. Han, S-W. Kim, A. Spira, E.B. Haura, J.K. Sabari, R.E. Sanborn, J.M. Bauml, J.E. Gomez, P. Lorenzini, J.R. Infante, J. Xie, N. Haddish-Berhane, M. Thayu, R.E. Knoblauch, K. Park
Journal: Annals of Oncology (2020)